Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2010-05-10 Share Issue/Capital Cha…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma SA publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 30 avril 2010
Share Issue/Capital Change Classification · 98% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 30 AVRIL 2010" (New number of shares and voting rights as of April 30, 2010). It explicitly states it is published in accordance with French commercial code (Code de Commerce) and AMF regulations (Autorité des marchés financiers) to report the total number of shares and voting rights. This type of mandatory disclosure regarding the capital structure and voting power is a specific regulatory filing. While it relates to capital structure, the core purpose is the mandatory reporting of share count changes, which often falls under general regulatory announcements or specific capital change notifications. Given the options, 'Share Issue/Capital Change' (SHA) is relevant, but the document is a formal regulatory disclosure of the current share count, often required periodically. Since it is a formal announcement detailing the exact number of shares and voting rights based on a specific date, it fits best under a general regulatory filing or a capital change notification. Because it is a direct, formal disclosure of the share count, 'SHA' (Share Issue/Capital Change) is the most precise fit among the specific options, as the share count is the fundamental basis for capital structure reporting. It is not a general earnings release (ER) or a full annual report (10-K). It is a specific regulatory disclosure about the capital base.
2010-05-10 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at April 30, 2010
Share Issue/Capital Change Classification · 95% confidence The document explicitly states its purpose: to release the 'Total number of shares outstanding as well as its voting rights as at April 30, 2010,' pursuant to French commercial code and AMF regulations. This type of mandatory disclosure regarding the total share count and voting rights is a specific regulatory filing related to capital structure and ownership transparency. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). While it relates to share capital, it is a specific regulatory disclosure about the total number of shares and voting rights, which fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-standard report, or potentially 'Share Issue/Capital Change' (SHA) if the focus was on a change, but here it is a periodic update on the total count. Given the specific nature of reporting total shares and voting rights under AMF rules, and the lack of a dedicated code for 'Shares Outstanding Report', RNS (Regulatory Filings) is the most appropriate fallback for this mandatory, periodic regulatory disclosure that doesn't fit the other specific categories like DIRS (insider trades) or DIV (dividends). However, since it is a direct notification about the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, it is closely related to share capital changes. Given the options, RNS is the safest general regulatory classification for this specific AMF disclosure.
2010-05-10 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’affaires trimestriel au 31 mars 2010 et fait le point sur sa trésorerie
Earnings Release Classification · 95% confidence The document is a press release announcing quarterly revenue and cash position for Innate Pharma as of March 31, 2010. It provides key financial highlights (revenue, cash, and debt) for the period. While it contains financial data, it is a short, high-level summary announcement rather than a full, comprehensive interim financial report. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) is classified as an Earnings Release (ER). Q1 2010
2010-05-05 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first quarter of 2010 and updates on its cash situation
Earnings Release Classification · 99% confidence The document is titled "INNATE PHARMA ANNOUNCES ITS TURNOVER FOR THE FIRST QUARTER OF 2010 AND UPDATES ON ITS CASH SITUATION". It provides key financial highlights (turnover, cash position) for a specific fiscal period (First Quarter of 2010). This format, focusing on initial, summarized results rather than comprehensive statements (like a 10-K or IR), strongly indicates an Earnings Release (ER). The document length (3790 chars) is consistent with a press release announcing results, not a full regulatory report. Q1 2010
2010-05-05 English
DOCUMENT DE REFERENCE ET RAPPORT FINANCIER ANNUEL, INNATE PHARMA SA
Annual Report Classification · 100% confidence The document is titled 'DOCUMENT DE REFERENCE RAPPORT FINANCIER ANNUEL' (Annual Financial Report/Reference Document) and explicitly mentions it was filed with the AMF (Autorité des marchés financiers). It contains comprehensive financial statements, audit reports, management discussion and analysis, and corporate governance information for the fiscal year. This aligns with the definition of an Annual Report (10-K equivalent in the French market context). FY 2009
2010-04-29 French
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la mise à disposition de son Document de Référence et de son Rapport Annuel 2009
Report Publication Announcement Classification · 99% confidence The document is a short press release (2837 characters) titled "INNATE PHARMA ANNONCE LA MISE A DISPOSITION DE SON DOCUMENT DE REFERENCE ET DE SON RAPPORT ANNUEL 2009" (Innate Pharma announces the availability of its Reference Document and its 2009 Annual Report). The core content is an announcement stating that the 'Document de Référence 2009' and the 'Rapport Annuel 2009' are available for download on the company website and the AMF website. This perfectly matches the definition of a Report Publication Announcement (RPA), which is used when a document announces the release of another report, rather than being the report itself (Rule 2: THE "MENU VS MEAL" RULE). Although it mentions the 'Rapport Annuel 2009' (which might suggest 10-K), the document's function is purely to announce its publication.
2010-04-29 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.